Assessing New Therapies for Retinal Diseases

Opinion
Video

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Video content above is prompted by the following:

  • New Therapies:
  • Aflibercept 8 mg
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Related Content
Korea Institute of Science and Technology (KIST) enters technology transfer agreement with Huons BioPharma

Korea Institute of Science and Technology (KIST) enters technology transfer agreement with Huons BioPharma

Sydney M Crago
January 6th 2025
Article
Spotlighting telemedicine in the year of a pandemic

Spotlighting telemedicine in the year of a pandemic

Alex Delaney-Gesing
October 19th 2020
Podcast
Ocular Therapeutix, Inc. set to present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix, Inc. set to present at the 43rd Annual J.P. Morgan Healthcare Conference

Sydney M Crago
December 28th 2024
Article
©Artur - stock.adobe.com

Ophthalmic safety notice: Potential fungal contamination prompts Systane Ultra PF voluntary recall

Lynda Charters;Sheryl Stevenson
December 27th 2024
Article
4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

Sydney M Crago
December 20th 2024
Article
EssilorLuxottica enters agreement for the acquisition of Espansione Group

EssilorLuxottica enters agreement for the acquisition of Espansione Group

Sydney M Crago
December 19th 2024
Article
© 2025 MJH Life Sciences

All rights reserved.